 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Regorafenib combined with orvizumab in the treatment of microsatellite stable advanced colorectal cancer

Clin Cancer Res: Regorafenib combined with orvizumab in the treatment of microsatellite stable advanced colorectal cancer

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

1 4 dichlorobutane

baclofen 20 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide.

Colorectal cancer blood vessels

Regorafenib is a small molecule tyrosine kinase inhibitor.

immunity

This study is a single-arm, multi-center phase II trial.

PFS and OS in microsatellite-stabilized patients treated with regorafenib + orvizumab

A total of 48 patients were recruited from 4 centers, and 43 of them could be evaluated for efficacy.

The best response is to maintain a stable condition, seen in 23 (53.

The prediction of tumor infiltration of CD163+ macrophages on the prognosis of patients

High baseline infiltration of tumor-associated macrophages was significantly associated with poor PFS (1.

In short, mAb Orville Ruige Fini joint portion can be mobilized anti microsatellite stable patients with colorectal cancer tumor immunity force.

Original source:

Sophie Cousin, et al.

aacrjournals.
org/content/27/8/2139" target="_blank" rel="noopener">Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.